



Broadview Ventures Promotes Thomas Needham to *Managing Director of Longview Ventures*

Boston, Massachusetts, May 6, 2025

Broadview Ventures, a mission-driven investment firm dedicated to accelerating the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke, today announces the promotion of Thomas Needham to Managing Director of Longview Ventures. Longview Ventures is an independent investment vehicle that makes follow-on investments in select Broadview portfolio companies, focused on clinical-stage opportunities, typically Series B and beyond, as a complement to Broadview's dedication to Seed and Series A financings. In his expanded role, Tom will focus on Longview Ventures' strategy and evolution, working closely with the Leducq Trust and Longview Investment Advisory Committee to drive success and impact across the growing Longview portfolio. He will also continue in his role as Head of BioPharmaceuticals at Broadview.

Tom has over 30 years of experience in venture capital investing, business development and C-suite executive management responsibilities in public and private biotechnology companies. In his 7-year tenure with Broadview as Director and Head of the Biopharmaceuticals practice, he has shared responsibility for all aspects of Broadview's investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement.

Tom was instrumental in both the original setup and structuring of the Longview investment strategy in 2018 and has played a leadership role in the successful portfolio build to 13 total investments. As a result of Tom's efforts, Longview now regularly co-invests alongside some of the industry's top tier medtech and biotech venture capital investors.

Since joining in 2018, Tom has closed 12 Broadview transactions, including nine new Broadview investments. Seven are new companies spun out of leading academic medical centers raising their first investor capital at time of investment. Tom currently serves on the boards of IsomAb and Basking Biosciences, including serving as Chairman (2020 thru 2023). He also serves as board observer at Comanche Bio, HAYA Therapeutics, and Alveron Pharma. Previously, Tom represented Broadview on the board at Antag Therapeutics, Renovacor (NYSE:RCOR, acquired by Rocket Pharma), including serving as Renovacor's Chairman (2019 thru 2021), and held board observer roles at NIDO Surgical (acquired) and Cardero Therapeutics (now Epirium Bio).

Prior to joining Broadview Ventures, Tom most recently was Chief Business Officer at Merrimack Pharmaceuticals (NASDAQ: MACK) and SVP, Business Development at C4 Therapeutics (NASDAQ: CCCC). Prior to that Tom spent 13 years as a healthcare and life science venture capital investor as Managing Director at Synthesis Capital and as a Principal at Advent International.

Tom's promotion demonstrates Broadview's strong commitment to the career progression and recognition of its investment team members. I look forward to continued partnership with Tom in his expanded leadership role across the Broadview and Longview organizations.



Christopher H. Colecchi
Managing Director

To learn more about Broadview and Longview portfolio and activities, please visit our [website](#).

Broadview Ventures | 265 Franklin Street | Boston, MA 02110 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!